RG
INDV icon

Rathbones Group’s Indivior Pharmaceuticals INDV Stock Holding History

Rathbones Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
40,949
+731
+2% +$26.5K 0.01% 320
2026
Q1 		$1.23M Sell
40,218
-1,872
-4% -$61.8K ﹤0.01% 337
2025
Q4 		$1.51M Sell
42,090
-706
-2% -$21.6K 0.01% 329
2025
Q3 		$1.03M Sell
42,796
-13,219
-24% -$277K ﹤0.01% 347
2025
Q2 		$832K Buy
56,015
+41,831
+295% +$487K ﹤0.01% 360
2025
Q1 		$133K Sell
14,184
-100
-0.7% -$1.05K ﹤0.01% 553
2024
Q4 		$183K Buy
14,284
+1,483
+12% +$15.3K ﹤0.01% 542
2024
Q3 		$126K Sell
12,801
-2,166
-14% -$25.4K ﹤0.01% 556
2024
Q2 		$235K Sell
14,967
-694
-4% -$12.5K ﹤0.01% 528
2024
Q1 		$335K Sell
15,661
-2,122
-12% -$39.9K ﹤0.01% 471
2023
Q4 		$269K Sell
17,783
-1,907
-10% -$33.9K ﹤0.01% 488
2023
Q3 		$427K Sell
19,690
-450
-2% -$10.3K ﹤0.01% 424
2023
Q2 		$467K Buy
+20,140
New +$462K ﹤0.01% 305

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rathbones Group's INDV Position: Q2 2026 in Review

Rathbones Group increased its Indivior Pharmaceuticals (INDV) stake by 1.8% in Q2 2026, buying an estimated $26.5K and bringing the position to 40,949 shares worth $1.68M. The position accounts for 0.01% of the portfolio, ranked #320.

Rathbones Group first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Rathbones Group held 40,949 shares of Indivior Pharmaceuticals worth $1.68M as of Q2 2026.
  • Rathbones Group bought 731 Indivior Pharmaceuticals shares in Q2 2026, an estimated $26.5K.
  • Indivior Pharmaceuticals made up 0.01% of Rathbones Group's portfolio in Q2 2026, its #320 holding.
  • Rathbones Group first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.